Annexon Inc Cash Flow Conversion Efficiency
Annexon Inc cash flow conversion efficiency. Based on the latest financial reports, Annexon Inc (ANNX) has a cash flow conversion efficiency ratio of -0.258x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-48.01 Million) by net assets ($186.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Annexon Inc (2017–2025)
Cash flow conversion efficiency of Annexon Inc from 2017 to 2025. This chart illustrates how Annexon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Annexon Inc stock price for real-time trading data and today's change.
Annexon Inc Cash Flow Conversion Ratio Explained
Annexon Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Annexon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexon Inc ranked by their cash flow conversion efficiency. Also see market value of Annexon Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
0.015x |
|
Xianheng International Science & Technology Co Ltd
SHG:605056
|
N/A |
|
Liberty Financial Group
AU:LFG
|
0.040x |
|
BHI Co. Ltd
KQ:083650
|
0.392x |
|
MCCORMICK+CO.INC. DL-01
F:MCX0
|
N/A |
|
Scanfil Oyj
HE:SCANFL
|
0.025x |
|
BMC Medical Co. Ltd. A
SHE:301367
|
N/A |
|
Avino Silver & Gold Mines Ltd
TO:ASM
|
0.043x |
Annual Cash Flow Conversion Efficiency for Annexon Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Annexon Inc from 2017 to 2025. Review ANNX FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $211.65 Million | $-186.36 Million | -0.880x | -118.70% |
| 2024-12-31 | $293.11 Million | $-118.01 Million | -0.403x | +16.73% |
| 2023-12-31 | $250.56 Million | $-121.14 Million | -0.483x | +3.89% |
| 2022-12-31 | $231.19 Million | $-116.31 Million | -0.503x | -9.95% |
| 2021-12-31 | $231.91 Million | $-106.11 Million | -0.458x | -196.73% |
| 2020-12-31 | $344.28 Million | $-53.09 Million | -0.154x | +76.33% |
| 2019-12-31 | $43.53 Million | $-28.36 Million | -0.651x | -43.56% |
| 2018-12-31 | $37.88 Million | $-17.19 Million | -0.454x | -208.88% |
| 2017-12-31 | $-46.21 Million | $-19.26 Million | 0.417x | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more